Javier MD - Arrowhead Pharmaceuticals Chief Officer
| 0HI3 Stock | 18.55 0.04 0.22% |
Executive
Javier MD is Chief Officer of Arrowhead Pharmaceuticals Corp
| Age | 59 |
| Address | 177 East Colorado Boulevard, Pasadena, CA, United States, 91105 |
| Phone | 626 304 3400 |
| Web | https://arrowheadpharma.com |
Arrowhead Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.4072) % which means that it has lost $0.4072 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (1.5184) %, meaning that it generated substantial loss on money invested by shareholders. Arrowhead Pharmaceuticals' management efficiency ratios could be used to measure how well Arrowhead Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Arrowhead Pharmaceuticals' Total Assets are comparatively stable compared to the past year. Non Current Assets Total is likely to gain to about 417.8 M in 2024, whereas Intangible Assets are likely to drop slightly above 10.2 M in 2024.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| BoHee Yoon | New Residential Investment | N/A | |
| Louise Coleman | Tatton Asset Management | N/A | |
| Stuart Biel | Federal Realty Investment | N/A | |
| Luke Sun | Silvercorp Metals | N/A | |
| Jamie Herd | Lords Grp Trading | N/A | |
| Harold Nafash | Federal Realty Investment | N/A | |
| Jan Sweetnam | Federal Realty Investment | 64 | |
| Kenneth Bruce | New Residential Investment | N/A | |
| Michael Linson | Federal Realty Investment | N/A | |
| Deirdre CRX | Federal Realty Investment | N/A | |
| Roddi VaughanThomas | Tatton Asset Management | N/A | |
| CGA MEcon | Silvercorp Metals | N/A | |
| Scott Adams | Tatton Asset Management | N/A | |
| Justine Randall | Tatton Asset Management | N/A | |
| Yi PEng | Silvercorp Metals | N/A | |
| Michael Kelleher | Federal Realty Investment | N/A | |
| Thi Jelf | Various Eateries PLC | N/A | |
| Jonathan Hoyles | Silvercorp Metals | N/A | |
| Leah Brady | Federal Realty Investment | N/A | |
| Claire Macneill | Tatton Asset Management | N/A | |
| David Schonbraun | New Residential Investment | 46 | |
Management Performance
| Return On Equity | -1.52 | |||
| Return On Asset | -0.41 |
Arrowhead Pharmaceuticals Leadership Team
Elected by the shareholders, the Arrowhead Pharmaceuticals' board of directors comprises two types of representatives: Arrowhead Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Arrowhead. The board's role is to monitor Arrowhead Pharmaceuticals' management team and ensure that shareholders' interests are well served. Arrowhead Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Arrowhead Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| CPA CPA, Chief Officer | ||
| Kenneth Myszkowski, Chief Officer | ||
| Javier MD, Chief Officer | ||
| Bruce MD, Chief Scientist | ||
| Vincent CFA, Head VP | ||
| MBA MD, Chief Medicine | ||
| Tracie Oliver, Chief Officer | ||
| Aaron Tan, Head Tax | ||
| Christopher Anzalone, President CEO | ||
| PharmD JD, COO Counsel | ||
| Nadia MBA, VP Treasurer | ||
| Mark Davis, Founder Calando | ||
| Howard Lovy, Director Communications | ||
| Mark Seefeld, Head VP |
Arrowhead Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Arrowhead Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.52 | |||
| Return On Asset | -0.41 | |||
| Operating Margin | (27.85) % | |||
| Current Valuation | 2.34 B | |||
| Shares Outstanding | 88.02 M | |||
| Shares Owned By Insiders | 4.46 % | |||
| Shares Owned By Institutions | 79.60 % | |||
| Price To Sales | 92.86 X | |||
| Revenue | 240.74 M | |||
| Gross Profit | 240.74 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Arrowhead Stock Analysis
When running Arrowhead Pharmaceuticals' price analysis, check to measure Arrowhead Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arrowhead Pharmaceuticals is operating at the current time. Most of Arrowhead Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Arrowhead Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arrowhead Pharmaceuticals' price. Additionally, you may evaluate how the addition of Arrowhead Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.